Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
VelaFi Completes $20M Series B Funding Round, Led by XVC and Ikuyo

VelaFi Completes $20M Series B Funding Round, Led by XVC and Ikuyo

BlockBeatsBlockBeats2026/01/12 13:07

BlockBeats News, January 12th, according to Coindesk, stablecoin financial infrastructure provider VelaFi has completed a $20 million Series B financing round, led by XVC and Ikuyo. Alibaba Investment, Planetree, BAI Capital, and other global investment institutions also participated in this round of financing, bringing the company's total funding to over $40 million.


Founded in 2020, VelaFi initially built payment infrastructure in Latin America and has now expanded its business to the U.S. and Asian markets. The platform integrates local banking channels, cross-border payment networks, and mainstream stablecoin protocols, enabling enterprises to achieve cross-market fund transfers faster and at a lower cost than traditional systems.


The company provides fiat-to-crypto onramps and offramps, payment solutions, cross-border payments, multi-currency accounts, foreign exchange tools, and asset management services, supporting access through the platform directly or via API interfaces.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny

CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.

智通财经•2026/11/09 06:37
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny